# Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

> **NCT05933447** · PHASE1 · COMPLETED · sponsor: **Altavant Sciences GmbH** · enrollment: 27 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rodatristat Ethyl
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo for Rodatristat
- **DRUG:** Placebo for Moxifloxacin

## Key facts

- **NCT ID:** NCT05933447
- **Lead sponsor:** Altavant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-12
- **Primary completion:** 2023-07-28
- **Final completion:** 2023-07-28
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933447, "Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05933447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*